Forbion Capital

Get funding

Forbion is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies that transform people’s lives.

Use: Go2Market;
Date closing: -
Amount: -
Industry focus: Health;
Total budget: 750M €
Entity type: Venture Capital
Vertical focus: Autoimmune & Inflammation, Cardiovascular/Metabolic, Central nervous system, Digestive & Renal, Oncology, Ophthamology, Orphan/rare disease, Respiratory.
Website: http://www.forbion.com/

Status:
Open
Funding type: Equity investment;
Geographic focus:
Public/Private: Private
Stage focus: Seed; Series A;
Applicant target: Startup;

Add a Review Send question

Overview

Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.

Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment further demonstrating our philosophy that investments in companies should positively impact the health and well-being of patients.

Their investment focus is on Autoimmune & Inflammation, Cardiovascular/Metabolic, Central nervous system, Digestive & Renal, Oncology, Ophthamology, Orphan/rare disease, Respiratory.

Forbion Capital Partners has raised a total of $2.8B across 9 funds, their latest being Forbion Growth Opportunities Fund II. This fund was announced on Jun 9, 2022 and raised a total of $500M.

Last April 2023 the firm announced the closing of the Forbion Ventures Fund VI, which is focused on new companies in early stages of development. It has raised 750 million euros. The firm also brought in 600 million euros for the Forbion Growth Opportunities Fund II.

Portfolio: Inversago, Bioinvent, Azafaros, Dyne.

Last updated on 2023-05-09 14:30